financetom
Business
financetom
/
Business
/
Fintech firm Pagaya's Q2 revenue rises 30%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fintech firm Pagaya's Q2 revenue rises 30%
Aug 7, 2025 4:47 AM

Overview

* Pagaya ( PGY ) Q2 revenue rises 30% yr/yr, driven by Auto and POS verticals

* Adjusted EBITDA for Q2 up 72% yr/yr, reflecting operational scalability

* Net income for Q2 reaches $17 mln, marking second consecutive positive quarter

Outlook

* Pagaya ( PGY ) expects 3Q25 network volume between $2.75 bln and $2.95 bln

* Company sees 3Q25 revenue between $330 mln and $350 mln

* Pagaya ( PGY ) forecasts FY25 adjusted EBITDA between $345 mln and $370 mln

* Company expects FY25 GAAP net income between $55 mln and $75 mln

Result Drivers

* REVENUE GROWTH - Driven by Auto and Point-of-Sale verticals, contributing to a 30% increase in total revenue and other income

* NETWORK VOLUME - Record $2.6 bln network volume, up 14% YoY, supported by growth in Auto and POS verticals and prudent underwriting

* ADJUSTED EBITDA - Increased by 72% YoY to $86 mln, benefiting from improved FRLPC and operating leverage

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Total $326 mln

Revenue

& Other

Income

Q2 Beat $51 mln $17.80

Adjusted mln (10

Net Analysts

Income )

Q2 Net $17 mln

Income

Q2 $86 mln

Adjusted

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the financial technology (fintech) peer group is "buy"

* Wall Street's median 12-month price target for Pagaya Technologies Ltd ( PGY ) is $30.50, about 2.8% below its August 6 closing price of $31.36

* The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved